Radiation oncology firm Accuray said that revenue increased by 5% for its first fiscal quarter (end-September 30).
Revenue increased from $86 million to $91 million, driven by product revenue growth of 9% as a backlog of orders from Europe, the Middle East, and Africa (EMEA) and also Japan were converted into sales.
The company's net loss for the period edged lower for the quarter, with the firm reporting a net loss of $9.4 million, compared with a net loss of $9.9 million in the corresponding quarter a year ago.
Accuray said it remains on track for its projected 2018 financial outlook.
